• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Novavax, Inc. - Common Stock (NQ:NVAX)

    6.340 +0.370 (+6.20%)
    Streaming Delayed Price Updated: 4:00 PM EDT, May 12, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 10,267,160
    Open 6.050
    Bid (Size) 6.300 (10)
    Ask (Size) 6.350 (11)
    Prev. Close 5.970
    Today's Range 6.040 - 6.450
    52wk Range 5.010 - 23.86
    Shares Outstanding 74,484,166
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Benzinga Bulls And Bears: IBM, Novavax, Arm Holdings — And UK Trade Deal Boosts Markets
    Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories. 
    Via Benzinga
    COVID Vaccine Maker Novavax Stock Soars 16% - Here's Why
    Novavax posts $667 million in Q1 2025 revenue and $2.93 EPS, boosted by Sanofi payments and APA terminations; full-year outlook raised above expectations. 
    Via Benzinga
    Exposures COVID-19

    Performance

    YTD
    -26.0%
    -26.0%
    1 Month
    -1.1%
    -1.1%
    3 Month
    -22.6%
    -22.6%
    6 Month
    -29.6%
    -29.6%
    1 Year
    -51.6%
    -51.6%

    More News

    Read More
    Thursday's Top 5 Trending Stocks: What's Going On With D-Wave, Novavax, Carvana?
    Via Benzinga
    Earnings Scheduled For May 8, 2025
    Via Benzinga
    Uncovering Potential: Novavax's Earnings Preview
    Via Benzinga
    Novavax Stock Rallies On Upbeat Q1 Earnings, Revised Full-Year Revenue Forecast: Retail’s Elated
    Via Stocktwits
    Exposures COVID-19 Product Safety
    12 Health Care Stocks Moving In Thursday's Pre-Market Session
    Via Benzinga
    Vinay Prasad's Appointment To FDA's CBER Triggers Questions Over Future Of Cell And Gene Therapy Regulation
    Via Benzinga
    Exposures Product Safety
    10 Health Care Stocks With Whale Alerts In Today's Session
    Via Benzinga
    Trump-Era FDA Appointees Request New Trials For Novavax COVID Vaccine, Reportedly Delaying Approval Timeline
    Via Benzinga
    Topics Government
    Exposures COVID-19 Political Product Safety
    Novavax Tops Weekly Retail Buzz Spike Amid FDA Trial Drama, COVID-19 Vaccine Approval Hopes
    Via Stocktwits
    Exposures COVID-19 Product Safety
    Benzinga Bulls And Bears: Netflix, Novavax, Intel — And The Market Begins To Bounce Back
    Via Benzinga
    Novavax's COVID-19 Vaccine Nears FDA Full Approval, Stock Jumps
    Via Benzinga
    Exposures COVID-19 Product Safety
    Amphenol Posts Better-Than-Expected Results, Joins SAP, Tesla, Pegasystems And Other Big Stocks Moving Higher On Wednesday
    Via Benzinga
    Novavax Signals Chances Of FDA Approval For Its COVID-19 Vaccine: But Retail Sentiment Wavers
    Via Stocktwits
    Topics Government
    Exposures COVID-19 Political Product Safety
    Novavax Covid Vaccine Shows Milder Side Effects Than Pfizer-BioNTech's Shot: Study
    Via Benzinga
    Exposures COVID-19
    Novavax Retail Traders Rally In Defense After RFK Jr.'s COVID-19 Vaccine Skepticism Sends Stock Tumbling
    Via Stocktwits
    Exposures COVID-19 Product Safety
    12 Health Care Stocks Moving In Thursday's Intraday Session
    Via Benzinga
    These stocks are gapping in today's session
    Via Chartmill
    2 Beaten-Down Stocks That Still Aren't Worth Buying
    Via The Motley Fool
    Topics Cannabis Government Law Enforcement
    Exposures Cannabis Legal Political
    Despite Headwinds, Biotech Sell-Off Could Offer Buying Opportunity: Analyst
    Via Benzinga
    Topics World Trade
    Exposures Product Safety Tariff
    Novavax Vaccine Approval From FDA In Limbo, Says Report – But Retail Is Hopeful
    Via Stocktwits
    Exposures COVID-19 Product Safety
    FDA Delays Full Approval Decision On Novavax's COVID-19 Vaccine
    Via Benzinga
    Exposures COVID-19 Product Safety
    Moderna, Novavax Shares Are Tumbling Monday: What's Going On?
    Via Benzinga
    Moderna, Vaxcyte, Novavax Hammered After Key FDA Official Peter Marks Resigns
    Via Investor's Business Daily
    Exposures Product Safety

    Frequently Asked Questions

    Is Novavax, Inc. - Common Stock publicly traded?
    Yes, Novavax, Inc. - Common Stock is publicly traded.
    What exchange does Novavax, Inc. - Common Stock trade on?
    Novavax, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Novavax, Inc. - Common Stock?
    The ticker symbol for Novavax, Inc. - Common Stock is NVAX on the Nasdaq Stock Market
    What is the current price of Novavax, Inc. - Common Stock?
    The current price of Novavax, Inc. - Common Stock is 6.340
    When was Novavax, Inc. - Common Stock last traded?
    The last trade of Novavax, Inc. - Common Stock was at 05/12/25 04:00 PM ET
    What is the market capitalization of Novavax, Inc. - Common Stock?
    The market capitalization of Novavax, Inc. - Common Stock is 472.23M
    How many shares of Novavax, Inc. - Common Stock are outstanding?
    Novavax, Inc. - Common Stock has 472M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms Of Service.